Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Journal
Cancer discovery
Journal Volume
12
Journal Issue
7
Pages
1676
Date Issued
2022-07-06
Author(s)
Wang, Mengzhao
Mitchell, Paul L
Fang, Jian
Camidge, D Ross
Nian, Weiqi
Chiu, Chao-Hua
Zhou, Jianying
Zhao, Yanqiu
Su, Wu-Chou
Yang, Tsung-Ying
Zhu, Viola W
Millward, Michael
Fan Y.
Huang, Wen-Tsung
Cheng, Ying
Jiang, Liyan
Brungs, Daniel
Bazhenova, Lyudmila
Lee, Chee Khoon
Gao, Bo
Xu, Yan
Hsu, Wei-Hsun
Zheng, Li
Jänne, Pasi A
Abstract
Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to a lack of effective therapy, the prognosis of these patients is typically poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily. The most common drug-related adverse events included diarrhea and skin rash. Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFRexon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response has not been reached.
Subjects
1ST-LINE TREATMENT; OPEN-LABEL; MOLECULAR HETEROGENEITY; AZD9291; CHEMOTHERAPY; RESISTANCE; GEFITINIB
Publisher
AMER ASSOC CANCER RESEARCH
Type
journal article